

03-16-06

ITW

Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 10/723,589

Filing Date November 25, 2003

First Named Inventor PRUSINER, STANLEY B.

Group Art Unit 1615

Examiner Name

Total Number of Pages in This Submission

Attorney Docket Number UCAL-243

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Restriction Requirement; postcard
---	---	--

Remarks


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	KARL BOZICEVIC, 28,807 BOZICEVIC, FIELD & FRANCIS, LLP
Signature	
Date	March 14, 2006

EXPRESS MAIL LABEL NO. EV 687 636 960 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 687 636 960 US

RESPONSE TO RESTRICTION REQUIREMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Docket No.	UCAL-243
	Application No.	10/723,589
	Confirmation No.	7570
	Filing Date	November 25, 2003
	Examiner	
	Group Art Unit	1615

Sir:

This communication is submitted in response to the Restriction Requirement dated February 28, 2006. The Examiner therein required election of one of the following groups of claims:

Group I: Claims 1-16, drawn to a method of treating disease resulting from malformed proteins from a mammal comprising administering to said mammal a therapeutically effective amount of a bis-cyclic compound; wherein said bis-cyclic compound is characterized by clearing malformed proteins and by an ability to cross a blood brain barrier of said mammal;

Group II: Claims 17 and 18, drawn to a composition for treating livestock with malformed proteins comprising livestock feed and a bis-cyclic compound;

Group III: Claims 19 and 20, drawn to a method for clearing malformed proteins from livestock with the administering of a pharmaceutically effective amount of a composition comprising livestock feed and a bis-cyclic compound;

Group IV: Claims 21 and 22, drawn to a composition comprising livestock feed and a bis-compound comprising two tricyclic moieties covalently bound by a linking group;

Group V: Claims 24 and 25, drawn to a composition comprising a pharmaceutically acceptable carrier and a bis-cyclic compound of general formula I (Acridine); or

Group VI: Claims 26-28, drawn to a compound.

The Applicants hereby elect to prosecute the claims of Group I claims 1-16 with traverse. As stated in the MPEP §803, if search and examination of an entire application can be made without serious burden, the examiner must examine the entire application on the merits, even though the entire application includes claims to independent or distinct inventions. It is the


Applicants' position that it would not be unduly burdensome to perform a search on all of the claims together in the present application. Accordingly, the Applicants traverse the restriction requirement.

The Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number UCAL-243.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 14/MARCH/06

By: 
Karl Bozicevic
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\UCAL\243\rest req 2-28-06.doc